Factors influencing individual variability in the therapeutic response to corticosteroids in asthma

Current Respiratory Medicine Reviews

Volumn 2, Issue 2, 2006, Pages 197-209

  Spears, Mark ^a   Thomson, Neil C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Asthma; Concordance; Corticosteroid insensitivity; Corticosteroids; Pharmacogenetics; Smoking

Indexed keywords

ALLERGEN; ANTIASTHMATIC AGENT; ANTIOXIDANT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CILOMILAST; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DEXAMETHASONE; FLUTICASONE; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; HISTONE DEACETYLASE; I KAPPA B; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONTELUKAST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; PREDNISONE; ROFLUMILAST; SHORT ACTING DRUG; THEOPHYLLINE; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

AGE DISTRIBUTION; ASTHMA; CIGARETTE SMOKING; CLINICAL TRIAL; DIAGNOSTIC ERROR; DISEASE DURATION; DISEASE SEVERITY; DRUG CLEARANCE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRY POWDER; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENDER; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEALTH CARE DELIVERY; HEREDITY; HUMAN; INFECTION; INFLAMMATORY CELL; INHALER; NONHUMAN; PEAK EXPIRATORY FLOW; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RACE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIGNAL TRANSDUCTION; SMOKING CESSATION;

EID: 33745928445     PISSN: 1573398X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339806776843102     Document Type: Review

References (153)

1. Global initiative for asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop report NIH 02-3659 Updated 2003. Available from. http://www.ginasthma. com/workshop_revised.pdf, Bethesda, 2002.
2. Guideline A. British Guidelines on the Management of Asthma. Thorax 2003; 58(Suppl 1). il-i94.
3. Djukanovic R, Roche W, Wilson J, et al. Mucosal inflammation in asthma. Am Rev Resp Dis 1990; 142: 434-457.
4. Barnes PJ, Adcock IM. How Do Corticosteroids Work in Asthma? Ann Intern Med 2003; 139(5 Part 1): 359-370.
5. Barnes P, Pedersen S, Busse W. Efficacy and Safety of Inhaled Corticosteroids. New Developments. Am J Respir Crit Care Med 1998; 157(3): S1-53.
6. Leung D, Bloom J. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2003; 111(1): 3-22.
7. Adams N, Bestall J, Jones P. Inhaled budesonide for chronic asthma in children and adults. The Cochrane Database of Systematic Reviews 1999; Issue 4. Art. No. CD003274. DOI. 10.1002/14651858.CD003274
8. Adams N, Bestall J, Malouf R, Lasserson T, Jones P. Inhaled beclomethasone versus placebo for chronic asthma. The Cochrane Database of Systematic Reviews 2005; Issue 1. Art. No. CD002738. DOI. 10.1002/ 14651858.CD002738.pub2.
9. Adams N, Bestall J, Lasserson T, Jones P. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma. The Cochrane Database of Systematic Reviews 2004; Issue 2. Art. No. CD0023 10. DOI. 10.1002/14651858.CD002310.pub2.
10. Lanes S, Garcia Rodriguez L, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002; 57: 683-686.
11. Sin D, Man J, Sharpe H, Gan W, Man S. Pharmacological management to reduce exacerbations in adults with asthma. a systematic review and meta-analysis. JAMA 2004; 292: 367-376.
12. Adams N, Bestall J, Jones P. Inhaled fluticasone at different doses for chronic asthma. The Cochrane Database of Systematic Reviews 2000; Issue 4. Art. No. CD003534. DOI. 10.1002/14651858. CD003534.
13. Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma. a meta-analysis. Eur Respir J 2004; 23(4): 552-558.
14. Adams N, Bestall J, Jones P. Inhaled budesonide at different doses for chronic asthma. The Cochrane Database of Systematic Reviews 2000; Issue 2. Art. No. CD003271. DOI. 10.1002/14651858. CD003271.
15. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 2004; 59(l): 16-20.
16. Adams N, Bestall J, Jones P. Inhaled beclomethasone at different doses for chronic asthma. The Cochrane Database of Systematic Reviews 1999; Issue 4. Art. No. CD002879. DOI. 10.1002/ 14651858.CD002879.
17. Powell H, Gibson PG. Initial starting dose of inhaled corticosteroids in adults with asthma. a systematic review. Thorax 2004; 59(12): 1041-1045.
18. Currie G, Fower S, Lipworth B. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness. a meta-analysis. Ann Allergy Asthma Immunol 2003; 90: 194-198.
19. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma. A Randomized, Controlled Trial. Ann Intern Med 1999; 130(6): 487-495.
20. Szefler S, Martin R, King T, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109(3): 410-418.
21. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115(2): 233-242.
22. Stempel DA, Fuhlbrigge AL. Defining the responder in asthma therapy. J Allergy Clini Immunol 2005; 115(3): 466-469.
23. Tantisira K, Lake S, Silverman E, et al. Corticosteroid pharmacogenetics. association of sequence variants in CRHRI with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13: 1353-9.
24. Tantisira KG, Hwang ES, Raby BA, et al. TBX21. A functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci 2004; 101 (52): 18099-18104.
25. Colice GL, Stampone P, Leung DYM, Szefler SJ. Oral corticosteroids in poorly controlled asthma. J Allergy Clin Immunol. 2005; 115(1): 200-201.
26. Wallace A, Sandford A. Therapeutic response to asthma medications. genotype predictors. Treat Respir Med 2004; 3(3): 161-171.
27. Sayers I, Hall I. Pharmacogenetic approaches in the treatment of asthma. Curr Allergy Asthma Rep 2005; 5(2): 101-108.
28. Wechsler ME, Israel E. How Pharmacogenomics will Play a Role in the Management of Asthma. Am J Respir Crit Care Med 2005; 200412-1635OE.
29. Lane S, Arm J, Staynov D, Lee T. Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma. Am J Respir Cell Mol Biol 1994; 11 (1): 42-48.
30. Huizenga N, De Lange P, Koper J, et al. Five patients with biochemical and/or clinical generalised glucocorticoid resistance without alterations in the glucocorticoid receptor gene. J Clin Endocrinol Metab 2000; 85(5): 2076-2081.
31. Huizenga N, Koper J, de Lange P, et al. A polymorphism in the glucocorticoid receptor gene may be associated with an increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998; 83(l): 144-151.
32. Panarelli M, Holloway CD, Fraser R, et al. Glucocorticoid Receptor Polymorphism, Skin Vasoconstriction, and Other Metabolic Intermediate Phenotypes in Normal Human Subjects. J Clin Endocrinol Metab 1998; 83(6): 1846-1852.
33. Szabo S, Kim S, Costa G, Zhang X, Fathman C, Glimcher L. A novel transcription factor, T-bet, directs Thl lineage commitment. Cell 2000; 100: 655-669.
34. Finotto S, Neurath MF, Glickman JN, et al. Development of Spontaneous Airway Changes Consistent with Human Asthma in Mice Lacking T-bet. Science 2002; 295(5553): 336-338.
35. The Childhood Asthma Management Program Research Group. Long-Term Effects of Budesonide or Nedocromil in Children with Asthma. N Engl J Med 2000; 343(15): 1054-1063.
36. Herland K, Akselsen J, Skjonsberg O, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Resp Med 2005; 99: 11-19.
37. Althuis M, Sexton M, Prybylski D. Cigarette smoking and asthma symptom severity among adult asthmatics. J Asthma 1999; 36(3): 257-264.
38. Siroux V, Pin I, Oryszcyn MP, Le Moual N, Kauffmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study. Eur Respir J 2000; 15: 470-477.
39. Sippel JM, Pedula KL, Vollmer WM, Buist AS, Osborne ML. Associations of Smoking With Hospital-Based Care and Quality of Life in Patients With Obstructive Airway Disease. Chest 1999; 115(3): 691-696.
40. Silverman RA, Boudreaux ED, Woodruff PG, Clark S, Camargo CA Jr. Cigarette Smoking Among Asthmatic Adults Presenting to 64 Emergency Departments. Chest 2003; 123(5): 1472-1479.
41. Turner M, Noertjojo K, Vedal S, Bai T, Crump S, Fitzgerald J. Risk factors for near fatal asthma A case-control study in hospitalized patients with asthma. Am J Respir Crit Care Med 1998; 157: 1804-1809.
42. Walsh LJ, Wong CA, Cooper S, Guhan AR, Pringle M, Tattersfield AE. Morbidity from asthma in relation to regular treatment. a community based study. Thorax 1999; 54(4): 296-300.
43. Apostol G, Jacobs D, Tsai A, et al. Early life factors contribute to the decrease in lung function between ages 18 and 40. Am J Respir Crit Care Med 2002; 166: 166-172.
44. Lemiere C, Boulet L. Cigarette smoking and asthma. A dangerous mix. Can Respir J 2005; 12: 79-80.
45. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004; 24(5): 822-833.
46. Thomson N, Chaudhuri R, Livingston E. Active cigarette smoking and asthma. Clin Exp Allergy 2003; 33: 1471-1475.
47. Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease. inactivation of histone deacetylase. The Lancet 2004; 363(9410): 731-733.
48. Chalmers GW, Macleod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57(3): 226-230.
49. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168(11): 1308-1311.
50. Tomlinson JEM, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005; 60(4): 282-287.
51. Pedersen B, Dahl R, Karlstrom R, Peterson C, Venge P. Eosinophil and neutrophil activity in asthma in one-year trial with inhaled budesonide. Am J Respir Crit Care Med 1996; 153: 1519-1529.
52. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15 year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194-1200.
53. James AL, Palmer LJ, Kicic E, et al. Decline in Lung Function in the Busselton Health Study. the Effects of Asthma and Cigarette Smoking. Am J Respir Crit Care Med 2004: 200402-230OC.
54. Halterman J, Szilagyi P, Yoos H, et al. Benefits of a school-based asthma treatment prpgram in the absence of secondhand smoke exposure. Arch Pediatr Adolesc Med 2004; 158: 460-467.
55. Schaaf M, Cidlowski J. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 2003; 83: 37-48.
56. Barnes PJ. Corticosteroid Resistance in Airway Disease. Proc Am Thorac Soc 2004; 1(3): 264-268.
57. Chalmers G, MacLeod K, Thomson L, Little S, McSharry C, Thomson N. Smoking and airway inflammation in patients with mild asthma. Chest 2001; 120(6): 1917-1922.
58. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57(10): 875-879.
59. Meagher L, Cousin J, Secki J, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996; 156: 4422-4428.
60. Byron Y, Varigos G, Wootton A. IL-4 production is increased in cigarette smokers. Clin Exp Immunol 1994; 95: 333-336.
61. Keatings V, Collins P, Scott D, Barnes P. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obsrtuctive pulmonary disease and asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
62. Churg A, Dai J, Changshi Y, Wright J., Tumour necrosis factor-α is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med 2002; 166: 849-854.
63. Kam J, Szefler S, Surs W, Sher E, Leung D. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to Glucocorticoids. J Immunol 1993; 151(7): 3460-3466.
64. Franchimont D, Martens H, Hagelstein M-T, et al. Tumor Necrosis Factor α Decreases, and Interleukin-10 Increases, the Sensitivity of Human Monocytes to Dexamethasone. Potential Regulation of the Glucocorticoid Receptor. J Clin Endocrinol Metab 1999; 84(8): 2834-2839.
65. Takanashi S, Hasegawa Y, Kanehira Y, et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD) and smokers. Eur Respir J 1999; 14: 309-314.
66. Irusen E, Matthews J, Takahashi A, Barnes P, Chung K, Adcock I. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity. Role in steroid-insensitive asthma. J Allergy Clin Immunol 2002; 109(4): 649-657.
67. Hawrylowicz C, Richards D, Loke T-K, Christopher Corrigan C, Lee T. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant patients. J Allergy Clin Immunol 2002; 109(2): 369-370.
68. Hamid Q, Wenzel S, Hauk P, et al. Increased glucocorticoid receptor β in the airway cells of glucoerticoid-insensitive asthma. Am J Respir Crit Care Med 1999; 159: 1600-1604.
69. Sousa A, Lane S, Cidlowski J, Staynov D, Lee T. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor β-isoform. J Allergy Clin Immunol 2000; 105(5): 943-950.
70. Hauk P, Goleva E, Strickland I, et al. Increased glucocorticoid receptor β expression converts mouse hybridoma cells to a corticosteroid-insensitive phenotype. Am J Respir Cell Mol Biol 2002; 27: 361-367.
71. Oakley RH, Jewell CK Yudt MR, Bofetiado DM, Cidlowski JA. The Dominant Negative Activity of the Human Glucocorticoid Receptor β Isoform. Specificity and mechanisms of action. J. Biol. Chem 1999; 274(39): 27857-27866.
72. Pujols L, Mullol J, Perez M, et al. Expression of the human glucocorticoid receptor a and β isoforms in human respiratory epithelial cells and their regulation by dexamethasone. Am J Respir Cell Mol Biol 2001; 24: 49-57.
73. Leung D, Hamid Q, Vottero A, et al. Association of Glucocorticoid Insensitivity with Increased Expression of Glucocortocoid Receptor β J Exp Med 1997; 186(9): 1567-1574.
74. Strickland I, Kisich K, Hank PJ, et al. High Constitutive Glucocorticoid Receptor β in Human Neutrophils Enables Them to Reduce Their Spontaneous Rate of Cell Death in Response to Corticosteroids. J Exp Med 2001; 193(5): 585-594.
75. Webster J, Oakley R, Jewell C, Cidlowski J. Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative β isoform. A mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci 2001; 98(12): 6865-6870.
76. Torrego A, Pujols L, Roca-Ferrer J, Mullol J, Xaubet A, Picado C. Glucocorticoid Receptor Isoforms α and β in in vitro Cytokine-induced Glucocorticoid Insensitivity. Am. J. Respir. Crit. Care Med 2004; 170(4): 420-425.
77. Verheggan M, Adriaansen-Soeting P, Berrevoets C, et al. Glucocorticoid receptor expression in human bronchial epithelial cells. effects of smoking and COPD. Mediat Inflamm 1998; 7: 275-81.
78. Galigniana MD, Piwien-Pilipuk G, Assreuy J. Inhibition of Glucocorticoid Receptor Binding by Nitric Oxide. Mol Pharmacol 1999; 55(2): 317-323.
79. Spahn J, Landwehr L, Nimmagadda S, Surs W, Leung D, Szefler S. Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma. J Allergy Clin Immunol 1996; 98(6):1073-1079.
80. Livingston E, Darroch C, Chaudhuri R, et al. Glucocorticoid. receptor α to β ratio in blood mononuclear cells is reduced in cigarette smokers. J Allergy Clin Immunol 2004; 114: 1475-1478.
81. Laustiola K, Lassilia R, Kaprio J, Koskenvuo M. Decreased β- adrenergie receptor density and catecholamine response in male cigarette smokers. a study of monozygotic twin pairs discordant for' smoking. Circulation 1988; 78: 1234-1240.
82. 2-adrenoceptor. a study of monitoring smoking cessation. J Cardiovasc Pharmacol 1991; 17: 923-938.
83. 2-adrenergic receptors in human macrophage/monocytic (U937) cells. Am J Respir Crit Care Med 2004; 169: A848.
84. 2-Agonists in Asthma and Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 2004; 1(3): 200-206.
85. Wang J, Manning B, Wu Q, Blankson S, Bouchier-Hayes D, Redmond H. Endotoxin/Lipopolysaccharide Activates NF-KB and Enhances Tumor Cell Adhesion and Invasion Through a β 1 Integrin-Dependent Mechanism. J Immunol 2003; 170: 795-804.
86. Bantel H, Schmitz M, Raible A, Gregor M, Schulze-Osthoff K. Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness. FASEB J 2002; 16(13): 1832-1834.
87. Rahman I, MacNee W. Role of transcription factors in inflammatory lung disease. Thorax 1998; 53(7): 601-612.
88. Ito K, Caramori G, Lim S, et al. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002; 166(3): 392-396.
89. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation. importance in inflammatory lung diseases. Eur Respir J 2005; 25(3): 552-563.
90. Ito K, Lim S, Caramori G, Chung K, Barnes P, Adcock I. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001; 15(6): 1110-1112.
91. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline Restores Histone Deacetylase Activity and Steroid Responses in COPD Macrophages. J Exp Med 2004; 200: 689-695.
92. Mochida-Nishimura K, Surewicz K, Cross J, et al., Differential activation of MAP kinase signalling pathways and nuclear factor-kappaB in bronchoalveolar cells of smokers and nonsmokers. Mol Med 2001; 7: 177-185.
93. Kennedy S, Elwood R, Wiggs B, Pare P, Hogg J. Increased airway mucosal permeability of smokers. relationship to airway reactivity. Am Rev Resp Dis 1984; 129: 143-148.
94. 99mTc-DTPA in asthma. Am Rev Resp Dis 1988; 139:1139-1143.
95. Cerveri I, Accordini S, Corsico A, et al. Chronic cough and phlegm in young adults. Eur Respir J 2003; 22: 413-417.
96. Invernizzi G, Ruprecht A, Paredi P, et al. Particle size of dry powder fluticasone is modified in the presence of tobacco smoke. Eur Respir 12004; 34(Suppl 48). 28s.
97. Rose J, Yurchak A, Meikle A, et al., Effect of smoking on prednisone, prednisolone, and dexamethasone pharmacokinetics. J Pharmacokinet Biopharm 1981; 9: 1-14.
98. Zevin S, Benowitz N. Drug interactions with tobacco smoking. Clin Pharmacokinetics 1999; 36(6): 425-438.
99. Murray CS, Simpson A, Custovic A. Allergens, Viruses, and Asthma Exacerbations. Proc Am Thorac Soc 2004; 1(2): 99-104.
100. Platts-Mills TAE. Allergen avoidance. J Allergy Clin Immunol 2004; 113(3): 388-391.
101. Halken S, Host A, Niklassen U, et al. Effect of mattress and pillow encasings on children with asthma and house dust mite allergy. J Allergy Clin Immunol 2003; 11l(l): 169-176.
102. Mihrshahi S, Peat J, Marks G, et al. Eighteen-month outcomes of house dust mite avoidance and dietary fatty acid modification in the childhood asthma prevention study (CAPS). J Allergy Clin Immunol 2003; 11l(l): 162-168.
103. Nimmagadda S, Szefler S, Spahn J, Surs W, Leung D. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Am J Respir Crit Care Med 1997; 155: 87-93.
104. Larsson S, Hansson L, Greiff L, et al. Natural allergen exposure does not diminish the sensitivity of cytokine production to glucocorticoids in blood cells of seasonal allergic asthma and rhinitis patients. Resp Med 2002; 96: 927-933.
105. Hauk P, Hamid Q, Chrousos G, Leung D. Induction of corticosteroid insensitivity in human PBMCs by microbial superantigens. J Allergy Clin Immunol 2000; 105(4): 782-787.
106. Li L-b, Goleva E, Hall CF, Ou L-S, Leung DYM. Superantigeninduced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol 2004; 114(5): 1059-1069.
107. Fakhri S, Tulic M, Christodoulopoulos P, et al. Microbial superantigens induce glucocorticoid receptor beta and steroid resistance in a nasal explant model. Laryngoscope 2004; 114: 887-892.
108. Yamada K, Elliott WM, Bransand R, Valeur A, Hogg JC, Hayashi S. Molecular mechanisms of decreased steroid responsiveness induced by latent adenoviral infection in allergic lung inflammation. J Allergy Clin Immunol 2002; 109(l): 35-42.
109. Little SA, MacLeod KJ, Chalmers GW, Love JG, McSharry C, Thomson NC. Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma. Am J Med 2002; 112(6): 446-452.
110. Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24(l): 122-128.
111. Vignola AM, Mirabella F, Costanzo G, et al. Airway Remodeling in Asthma. Chest 2003; 123: 417S-422S.
112. Hsu J-Y, King S-L, Kuo B-T, Chiang C-D. Age of onset and the characteristics of asthma. Respirology 2004; 9(3): 369-372.
113. Pizzichini M. Is sputum eosinophilia a good or poor predictor of benefit from inhaled corticosteroid therapy in asthma? Eur Respir J 2002; 20:1359-1361.
114. Wenzel S, Schwartz L, Langmack E, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001-1008.
115. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung K, Barnes P. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160: 1532-1539.
116. Gibson PG, Simpson JL, Saltos N. Heterogeneity of Airway Inflammation in Persistent Asthma. Evidence of Neutrophilic Inflammation and Increased Sputum Interleukin-8. Chest 2001; 119(5):1329-1336.
117. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts. a randomised controlled trial. The Lancet 2002; 360(9347): 1715-1721.
118. Wenzel SE. Phenotypes in Asthma. Useful Guides for Therapy, Distinct Biological Processes, or Both? Am J Respir Crit Care Med 2004; 170(6): 579-580.
119. The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22(3): 470-477.
120. Proceedings of the ATS Workshop on Refractory Asthma. Current Understanding, Recommendations, and Unanswered Questions. Am J Respir Crit Care Med 2000; 162(6): 2341-2351.
121. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. Systematic assessment of difficult-to-treat asthma. Eur Respir J 2003; 22(3): 478-483.
122. Heaney L, Robinson D. Severe asthma treatment. need for characterising patients. Lancet 2005; 365: 974-974.
123. Williams L, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004; 114: 1288-1293.
124. Bender B, Milgrom H, Apter A. Adherence Intervention Research. What Have We Learned and What Do We Do Next? J Allergy Clin Immunol 2003; 112(3): 489-494.
125. Federico MJ, Covar RA, Brown EE, Leung DYM, Spahn JD. Racial Differences in T-Lymphocyte Response to Glucocorticoids. Chest 2005; 127(2): 571-578.
126. Molyneux A. ABC of smoking cessation. Nicotine replacement therapy. Br Med J 2004; 326: 454-456.
127. Molyneux A, Lewis S, Leivers U, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief councelling, brief councelling alone and minimal intervention on smoking cessation in hospital in-patients. Thorax 2003; 58: 484-488.
128. NICE report A rapid and systematic review of the clinical and cost effectiveness of bupropion SR and nicotine replacement therapy (NRT) for smoking cessation. vol 2004. www.nice.org.uk, 2002.
129. Wakefields M, Ruffin R, Campbell D, Roberts L, Wilson D. Smoking-related beliefs and behaviour among adults with asthma in a representative population sample. Aust N Z J Med 1995; 25(l): 12-17.
130. Eisner M, Yelin E, Katz P, Shoiboski S, Henke J, PBlanc P. Predictors of cigarette smoking and smoking cessation among adults with asthma. Am J Public Health 2000; 90(8): 1307-1311.
131. Report of the Surgeon General. The Health Benefits of Smoking Cessation. Bethesda, USA. Public Health Services (Office on Smoking and Health), 1990; 1-627.
132. Willemse B, Postma DS, Timens W, ten Hacken NHT. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23: 464-476.
133. Anthonisen NR, Connett JE, Murray RP. Smoking and Lung Function of Lung Health α to β Study Participants after II Years. Am J Respir Crit Care Med 2002; 166(5): 675-679.
134. Higenbottam T, Feyeraband C, Clark T. Cigarette smoking in asthma. Br J Dis Chest 1980; 74: 279-284.
135. Hillerdahl G, Rylander R. Asthma and smoking cessation. Clin Allergy 1984; 14: 45-47.
136. Fennerty A, Banks J, Ebden P, Bevan C. The effect of cigarette withdrawal on asthmatics who smoke. Eur J Repir Dis 1987; 71(5): 395-399.
137. Ito K, Caramori G, Cosio M, Chung K, Adcock IM, Barnes P. A molecular mechanism of action of theophylline. induction of histone deacetylase to decrease inflammatory gene expression. Proc Natl Acad Sci 2002; 99: 8921-8926.
138. Ito K, Barnes P, Adcock I. Glucocorticoid receptor recruitment of histine deacetylase 2 inhibits IL-1 β-induced histone H4 acetylation on lysine 8 and 12. Mol Cell Biol 2000; 20: 6891-6903.
139. 2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191.
140. Johnson M, Rennard S. Alternative mechanisms for long-acting β2-adrenergic agonists in COPD. Chest 2001; 120: 258-270.
141. Calverley P, Pauwels R, Vestbo J, et al. Combination salmeterol and fluticasone in the treatment of chronic obstructive pulmonary. a randomised controlled trial. Lancet 2003; 361: 449-456.
142. Fauler J, Frolich J. Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 1997; 27: 43-47.
143. Zhu J, Kilty I, Granger H, et al. Gene Expression and Immunolocalization of 15-Lipoxygenase Isozymes in the Airway Mucosa of Smokers with Chronic Bronchitis. Am J Respir Cell Mol Biol 2002; 27(6): 666-677.
144. Compton C, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease. a randomised, dose ranging study. Lancet 2001; 353: 265-270.
145. Birrell MA, Patel HJ, McCluskie K, et al. PPAR-Υ agonists as therapy for diseases involving airway neutrophilia. Eur Respir J 2004; 24(l): 18-23.
146. Jiang. PPAR-Υ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
147. Patel HJ, Belvisi MG, Bishop-Bailey D, Yacoub MH, Mitchell JA. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids. Relevance for chronic obstructive pulmonary disease therapy. J Immunol 2003; 170(5): 2663-2669.
148. Harris S. Induction of apoptosis in mouse T cells upon peroxisome proliferator-activated receptor Υ (PPAR-Υ) binding. Adv Exp Med Biol 2002; 507: 421-25.
149. Barnes PJ. Chronic obstructive pulmonary disease 12. new treatments for COPD. Thorax 2003; 58: 803-808.
150. Caramori G, Adcock I. Pharmacology of airway inflammation in asthma and COPD. Pulm Pharmacol Therapeut 2003; 16: 247-277.
151. Caramori G, Papi A. Oxidants and asthma. Thorax 2004; 59: 170-173.
152. Poole P, Black P. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease. systematic review. BMJ 2001; 322(7297): 1271-
153. Adcock I, Caramori G. Kinase targets and inhibitors for the treatment of airway inflammatory diseases. the next generation of drugs for severe asthma and COPD? BioDrugs 2004; 18: 167-180.